Objective: This multicenter, open-label, single-arm, Phase II study assessed the efficacy of a neoadjuvant chemotherapy with docetaxel (75 mg/m 2 q3w) followed by 5-fluorouracil 500 mg/m 2 , epirubicin 100 mg/m 2 and cyclophosphamide 500 mg/m 2 q3w in patients with early-stage breast cancer. Methods: Women with resectable breast cancer (T1c -3 N0 M0 or T1 -3 N1 M0) were enrolled. Before surgery, patients received four cycles of docetaxel followed by four cycles of 5-fluorouracil, epirubicin, and cyclophosphamide. The primary endpoint was the pathological complete response ( pCR) rate defined for the breast alone, assessed by a central review committee. Secondary endpoints included clinical response and safety. Results: One hundred and thirty-seven patients were enrolled. Of the 132 patients assessable for pathologic response, 23% (95% confidence interval, 16 -31%) experienced a pathological complete response and 6% (95% confidence interval, 3-12%) had a near pathological complete response (few remaining cancer cells), resulting in a quasi-pathological complete response of 29% (95% confidence interval, 21 -37%). Clinical response rate following the initial docetaxel regimen was 64%. The overall clinical response rate after completion of 5-fluorouracil, epirubicin, and cyclophosphamide was 79%; breast-conserving surgery was performed in 79% of patients. More patients with triple-negative disease (estrogen/progesterone receptors negative; human epidermal growth factor 2 negative) experienced a pathological complete response [14/29, (48%); 95% confidence interval, 29 -68%] versus those with other molecular subtypes. The safety profile was acceptable. Conclusions: Eight cycles of neoadjuvant chemotherapy-docetaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide-are tolerable and conferred high rates of pathological complete response and breast-conserving surgery. Patients with triple-negative disease were more likely to achieve pathological complete response versus other subtypes, suggesting that selecting appropriate neoadjuvant chemotherapy based on molecular subtype could be possible.
INTRODUCTION
Neoadjuvant chemotherapy has been widely used for patients with operable breast cancer to increase the chance of breast conservation (1 -7) . Furthermore, response to neoadjuvant treatment can provide important information on long-term survival outcomes. Pathological complete response ( pCR) in the breast and axillary lymph nodes predicts a favorable prognosis, whereas a lack of pCR in the breast and node-positive status do not (6, 7) . This implies the possibility of tailoring subsequent treatment according to the response to initial treatment (7 -12) . In addition, correlative studies of tumor samples before and after treatment may provide information on markers that could predict response or resistance to treatment (13 -16) .
Results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18 trial demonstrated the impact of neoadjuvant chemotherapy in patients with operable early-stage breast cancer (17) . The protocolspecified anthracycline-containing regimen-four cycles of doxorubicin and cyclophosphamide (AC)-resulted in an increased likelihood of breast-conserving surgery (BCS) compared with no neoadjuvant chemotherapy. The study established pCR as a prognostic marker for long-term disease-free survival (DFS) and demonstrated that there was no difference in survival if chemotherapy was administered before or after surgery. Subsequent studies, such as the Aberdeen trial, have demonstrated the benefit of the sequential addition of taxanes to neoadjuvant anthracycline regimens (5) . The NSABP Protocol B-27 trial demonstrated that, compared with neoadjuvant AC alone, the addition of sequential docetaxel doubled the pCR rate, increased the clinical complete response rate (RR) and increased the proportion of patients with negative axillary nodes (7 -18) .
We previously conducted a Phase II study to evaluate the clinical and pathological response and safety of the FEC regimen (5-fluorouracil, epirubicin and cyclophosphamide) followed by docetaxel as neoadjuvant chemotherapy in Japanese women with early-stage breast cancer [Japan Breast Cancer Research Group (JBCRG) 01 trial]. The results of this study have been reported previously (19) . Although the pCR rate was 16% and BCS was possible for 85% of patients, there were some safety concerns, with 18% of patients experiencing febrile neutropenia and 41% of patients experiencing Grade 1/2 peripheral edema (no Grade 3/4 events observed) following the docetaxel regimen (unpublished data). Disease progression occurred in 6% of patients after the completion of all planned treatment (unpublished data).
In an effort to achieve a higher pathological RR with an improved safety profile, we decided to evaluate the efficacy and safety of docetaxel followed by FEC (JBCRG 03 trial)-the reverse of the sequence of chemotherapy used in the JBCRG 01 trial (19) . The clinical and pathological effects and the toxicity profile of this regimen are presented here, and the results of predictive marker analyses are discussed.
PATIENTS AND METHODS

PATIENT ELIGIBILITY
This was a multicenter, open-label, single-arm, Phase II study that recruited patients via central registration. Japanese women aged 20-59 years with histologically proven early-stage breast cancer (T1c -3 N0 M0 or T1 -3 N1 M0) were enrolled. No prior chemotherapy, radiotherapy, hormonal therapy or immunotherapy was allowed. Other inclusion criteria were Eastern Cooperative Oncology Group performance status 0 -1; white blood cell count 4000-12 000/mm 3 ; neutrophil count 2000/ mm 3 ; platelet count 100 000/mm 3 ; hemoglobin 9.5 g/dl; serum bilirubin 1.25 times upper limit of normal (ULN); creatinine 1.5 times ULN and aspartate aminotransferase and alanine aminotransferase 1.5 times ULN. Patients with congestive heart failure or left ventricular ejection fraction 60% were excluded. Patients were also excluded if they had confirmed infection; serious concomitant illness such as severe cardiovascular disease, uncontrolled diabetes, malignant hypertension or hemorrhagic disease; active concomitant malignancy; brain metastasis; peripheral neuropathy; history of edema with severe drug allergy; or previous long-term corticosteroid therapy. Pregnant or lactating women were excluded. Mammography, ultrasonography, magnetic resonance imaging or computed tomography was used to assess the presence of tumors. Baseline evaluations included complete blood cell and platelet count, routine blood chemistry and liver function tests, chest X-ray, bone scan, electrocardiogram and echocardiogram.
The local ethics committee or institutional review board approved the study at each institution. All patients gave written informed consent to participate. The protocol was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. 
TREATMENT
STATISTICAL METHODS
The primary endpoint was the pCR rate. Before the initiation of the current study, the pCR rate for non-taxane anthracycline regimens ranged from 12.8% (NSABP Protocol B-27) (18) to 15.4% (Aberdeen trial) (5). Previously, we had conducted JBCRG01 trial to evaluate the pCR rate defined for breast disease (19) . Therefore, in order to detect improvement in the pCR rate in the same definition of our previous study, a sample of 119 patients was required according to binominal distribution, with a one-sided threshold pCR rate of 12%, an expected pCR rate of 22%, an a error of 5% and a b error of 10%. The target number of patients for recruitment was therefore 119, so assuming that 5% of patients would not be evaluable, we planned to enroll 130 patients. Secondary endpoints included safety, clinical RR, rate of BCS, DFS, overall survival and a subset analysis according to biomarkers. Pathological and clinical RRs were calculated with 95% confidence intervals (95% CIs), with each complete RR based on a binominal distribution. Pathological response was evaluated by hormone receptor status and HER2 status. A multiple logistic regression analysis was performed to examine which factors (menopausal status, tumor size, ER and PgR status, HER2 status and clinical response to docetaxel and FEC) were associated with pCR and QpCR.
RESULTS
PATIENTS CHARACTERISTICS AND TREATMENT
Enrollment took place from October 2005 through October 2006. One hundred and thirty-seven patients were enrolled. Two patients did not receive study treatment because of early withdrawal of consent; therefore, 135 patients were evaluable for safety and clinical response. These evaluable Jpn J Clin Oncol 2011;41 (7) 869 patients included two patients aged 60 and 62 years (included because their age was not considered to influence the evaluation). Two patients were lost to follow-up before surgery, thus 133 patients were evaluable for surgical response. A total of 132 patients were evaluable for pathological response; one patient was excluded owing to lack of confirmation of invasive carcinoma (following the pathologic central review) due to inadequate samples from core needle biopsy before study treatment.
The patient characteristics are summarized in Table 1 . Thirty patients (22%) had triple-negative disease, defined as ER-negative, PgR-negative and HER2-negative primary breast cancer, including one patient who was lost to follow-up before surgery.
Overall, 98 patients (73%) completed the planned eight cycles of treatment without dose reductions or study discontinuation. A total of 115 (85%) and 106 (82%) patients completed all four planned treatment cycles of docetaxel and FEC, respectively; dose reductions were necessary in 9 (7%) and 17 (13%) patients, respectively. The majority of the dose reductions were attributable to toxicities, particularly febrile neutropenia during treatment with FEC (10 versus 2 patients during docetaxel treatment). Dose reductions due to neutropenia were required by three patients each during the docetaxel and FEC regimens. Eleven (8%) and six patients (5%), respectively, discontinued treatment during docetaxel and FEC therapy because of toxicities (five patients discontinued during both regimens) or disease progression (six patients during docetaxel and one patient during FEC). The mean dose intensities were 24.2 and 30.3 mg/m 2 /week for docetaxel and epirubicin, respectively.
TOXICITIES
The incidence of treatment-related AEs is summarized in Table 2 . Neutropenia was the most common Grade 3/4 treatment-related AE and was observed in 44% and 60% of patients during docetaxel and FEC therapy, respectively. Overall, 67% and 15% of patients experienced at least one episode of Grade 3/4 neutropenia or febrile neutropenia, respectively. For non-hematologic toxicities of any grade, rash, sensory neuropathy, edema, muscle pain and joint pain occurred more frequently during docetaxel treatment than with FEC. Conversely, the frequency of gastrointestinal symptoms, such as nausea, vomiting and anorexia, was higher with FEC than with docetaxel. The frequency of Grade 1/2 peripheral edema was similar during exposure to docetaxel (33%) and FEC (29%); no patient had Grade 3/4 edema. Grade 3/4 non-hematologic toxicities, including gastrointestinal disturbances, were infrequent during both docetaxel and FEC. No fatal AEs were reported.
CLINICAL RESPONSE TO TREATMENT
The overall clinical RR was 79% (106/135; 95% CI, 71 -85%), with a clinical complete RR of 21% (29/135), a partial RR of 57% (77/135) and a disease progression rate of 5% (7/135). The clinical RR following the initial docetaxel regimen was 64%. The clinical responses to treatment with docetaxel followed by FEC according to response to initial docetaxel are shown in Table 3 . Eight of the 135 patients (6%) progressed during docetaxel administration; 2 of 135 patients (1%) had disease progression during FEC. Of the 30 patients with triple-negative disease, 7 patients were observed to have disease progression following docetaxel treatment. One of the 17 patients with ER-positive, PgR-negative and HER2-negative tumors had disease Table 4 ). Excluding the differences outlined above, there were no differences between patient and tumor characteristics for those with progressive disease versus non-progressive disease. Twenty-seven of 48 non-responders to docetaxel (56%) had a response to FEC treatment; however, 8 of 87 responders to docetaxel (9%) showed no improvement in response with FEC treatment. Following chemotherapy, BCS was performed for 105 of 133 assessable patients (79%).
PATHOLOGICAL RESPONSE AND PREDICTIVE FACTORS TO TREATMENT
The primary endpoint-pCR rate-was 23% (95% CI, 16 -31%). A near pCR rate of 6% (95% CI, 3 -12%) resulted Jpn J Clin Oncol 2011;41 (7) 871 in a QpCR rate of 29% (95% CI, 21 -37%) when combined with the pCR. Pathological response of each subset population according to their hormone receptor and HER2 status is summarized in Fig. 1A and B. Patients with triple-negative disease had the highest pCR rate of 48% (95% CI, 29 -68%). Near pCR was not observed in triple-negative disease.
Patients with HER2-positive, ER-negative and PgR-negative tumors had a pCR rate of 29% (95% CI, 8 -58%) and a QpCR rate of 36% (95% CI, 13 -65%); patients with HER2-positive and ER-positive and/or PgR-positive tumors had a pCR rate of 19% (95% CI, 4 -46%) and a QpCR rate of 38% (95% CI, 15 -65%). Patients with HER2-negative and ER-positive and/or PgR-positive tumors had the lowest pCR and QpCR rates (13%; 95% CI, 6 -23% and 19%; 95% CI, 10 -30%, respectively). One of the seven patients who experienced clinical disease progression with initial docetaxel treatment had a QpCR following FEC. The relationship between tumor pathological feature and pCR rate is shown in Table 5 . The only variable found to be significantly associated with a pCR after docetaxel treatment was ER status. Survival outcomes will be reported when the 5-year follow-up has been completed for this study.
DISCUSSION
This is the first report to evaluate the effectiveness of an initial docetaxel regimen for neoadjuvant therapy of Japanese patients with early-stage breast cancer. An additional component of the study was to analyze the data according to hormone receptor and HER2 status. Recently, Wildiers et al. (22) reviewed four adjuvant trials which had demonstrated the taxane-first regimens were favorable in terms of the relative drug dose intensity achieved. Also they mentioned larger non-randomized adjuvant studies for a series of 284 patients who first received three cycles of FEC followed by three cycles of docetaxel, the mean relative dose intensity was 91% for FEC and 76% for docetaxel, whereas in another series of 378 patients who received three cycles of docetaxel followed by four cycles of EC (epirubicin plus cyclophosphamide), a median docetaxel dose intensity of 100% was achieved. Therefore, they concluded such data suggest that the administration of a taxane first, followed by an anthracycline, may be preferable in line with the NortonSimon hypothesis (23) . In the JBCRG 01 study, the largest study to date to evaluate neoadjuvant chemotherapy in this patient population, the clinical and pathological responses Triple-negative tumors were defined as ER-negative, PgR-negative and HER2-negative primary breast cancer.
872
Neoadjuvant docetaxel before anthracycline and safety of FEC followed by docetaxel were investigated (19) . The eligibility criteria, treatment dose and distribution of patient characteristics (menopausal status, tumor stage, hormone receptor status and HER2 status) studied in the JBCRG 01 trial were similar to those investigated in the present JBCRG 03 study (19) . The incidences of Grade 3/4 neutropenia and febrile neutropenia observed in the current study were similar to those reported in the JBCRG 01 trial (19) . However, the rate of Grade 1/2 edema during docetaxel treatment was lower in the present study (33%) than in the JBCRG 01 study (41%), suggesting that docetaxel might be better tolerated when given up front than when administered after completion of prior chemotherapy. Further studies are warranted to assess quality of life and the incidence of edema in order to confirm the effect of administering docetaxel as the initial therapy. Many different neoadjuvant chemotherapy schedules and dose regimens are used in clinical practice. The NSABP Protocol B-18 trial, which compared AC treatment before and after surgery, reported no difference in DFS between the two approaches (17) . However, the rate of BCS was greater with neoadjuvant AC chemotherapy, and the prognosis of patients who obtained a pCR was also better with this treatment regimen (17) . Several other regimens have been evaluated in an effort to increase the pCR rate. The addition of a taxane to an anthracycline-containing regimen has been shown to improve the pCR and clinical RRs (5, 18) . Furthermore, excellent results have been reported by the MD Anderson Cancer Center using a regimen of paclitaxel plus trastuzumab followed by FEC plus trastuzumab in patients with operable breast cancer and HER2 overexpression (24) . However, few studies have evaluated initial taxane therapy followed by an anthracycline-containing regimen in this indication (24) . Thus, it was decided to evaluate such a reverse regimen and to analyze the findings according to molecular subtypes. Importantly, the primary endpoint-pCR rateachieved in the present study was 23% (95% CI, 16 -31%), far exceeding our estimate of 12% (19) . Even though the pCR rate here cannot be directly compared with the results from the JBCRG 01 trial (pCR rate: 12%, QpCR rate: 25%), the pCR rate from this study is a favorable result considering the similar patient characteristics in both trials (19) .
The overall clinical RR of 79% was similar to that reported in the JBCRG 01 trial (74%) (19) . Furthermore, the clinical RR following the initial docetaxel regimen was 64%, similar to the clinical response following the initial FEC regimen in the JBCRG 01 trial (61%) (19) . The clinical RR following the initial docetaxel regimen, however, is lower in this study than those reported in other studies (71.7 -85%) (25, 26) . It could be hypothesized that the clinical response might be influenced by the lower dose of docetaxel used in this study (75 mg/m 2 ) compared with the 100 mg/m 2 dose used in previous studies (25, 26) . The rate of BCS observed in our study (79%) was similar to that reported in the JBCRG 01 trial (85%) (19) . Unfortunately, the overall disease progression rate (5%) was not lowered by the use of docetaxel followed by FEC in this study, and was similar to that seen in the JBCRG 01 trial (6%) (19) . Although 7 of the 29 patients with triple-negative disease had disease progression during the initial docetaxel regimen, 14 of the 22 patients without disease progression (64%) achieved a QpCR. This QpCR rate is markedly higher compared with previous findings (27) .
Our results indicate that if patients with triple-negative disease who experienced disease progression following initial docetaxel therapy were excluded, the pCR rate for this group of patients would have been higher. We thus compared the clinical and pathological characteristics between patients with triple-negative disease who experienced disease progression following the initial docetaxel regimen with those who did not have disease progression. However, no significant differences in patient or tumor characteristics were seen between these patient groups. It was noted, however, that six of seven premenopausal patients (86%) and four of seven patients (57%) with solid-tubular carcinoma had disease progression following docetaxel therapy. Given the high incidence of disease progression among patients with triple-negative disease who had solid-tubular subtype tumors, this phenotype could be used in future studies to predict which patients are more likely to experience progressive disease following docetaxel therapy. Accordingly, the identification of patients with hormone receptor-positive and HER2-negative disease would also enable the selection of patients who are more likely to benefit from neoadjuvant chemotherapy. Thus, studying patients' molecular subtypes, and selecting appropriate chemotherapy regimens accordingly, has the potential to provide superior results to those of the JBCRG 03 trial. Recently, it has been shown that basal-like breast cancer defined by five biomarkers [epidermal growth factor receptor (EGFR), cytokeratin 5/6 (CK5/6), ER, PgR and HER2 status] provides a more specific definition of basal-like breast cancer that predicts survival better than the triple-negative phenotype (27, 28) . In patients treated with anthracyclinebased chemotherapy, tumors found to be positive for the basal markers corresponded to a cohort of patients with a significantly worse outcome (29) . Thus in future trials, it may be beneficial to assess EGFR and CK5/6 status in patients with triple-negative disease to help predict patient survival.
Interestingly, the pCR rate (27%) following neoadjuvant chemotherapy in patients with HER2-negative breast cancer was higher in this study than in the JBCRG 01 study (14%), suggesting that this subpopulation may benefit from initial docetaxel treatment. Conversely, a lower QpCR rate was observed in HER2-positive patients (37%) in this study than in the JBCRG 01 trial (52.8%). This suggests that initial anthracyclines may be required for HER2-positive disease. A study by Buzdar et al. (24) reported that a high pCR rate of 60% was observed in patients with HER2-positive disease treated with the combination of paclitaxel plus trastuzumab followed by FEC plus trastuzumab, indicating that the HER2-positive population in the current study may have benefited further from concomitant trastuzumab therapy. These findings demonstrate the benefit of selecting the most effective chemotherapy regimen according to each patient's molecular subtype and initial response to neoadjuvant treatment.
One limitation of the study was that HER2-positive patients were not treated with trastuzumab, which has been shown to improve outcomes in patients with HER2-overexpressing breast cancer (24) . Further studies investigating optimal treatment regimens for different molecular subtypes should include concurrent trastuzumab for patients with the HER2-positive phenotype.
In conclusion, docetaxel followed by FEC as neoadjuvant chemotherapy is a tolerable and effective regimen for patients with early-stage breast cancer. In addition, a high pCR rate made this regimen particularly promising in patients with triple-negative breast cancer. In the future, selection of a neoadjuvant chemotherapy regimen for operable breast cancer may be possible based on molecular subtype.
